Mehdi Ansarinia, MD
Neurology · Las Vegas, NVNPI 1033233481
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $257,267 of the $305,708 with a category attached, or 84.2%. 32 manufacturers reported payments, led by AbbVie at 37.7% of the total. Reporting peaked in 2021 at $77,898 and has fallen 76.2% since, to $18,544 in 2025. Among neurology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 957 payments — averaging $319.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$115K
- Lilly USA, LLC$49K
- Amgen$46K
- Teva Pharmaceuticals USA, Inc.$25K
- Biohaven Pharmaceuticals, Inc.$22K
- Impel Pharmaceuticals Inc.$16K
- plus $32K from 26 others
Across 4 payments — averaging $641,500 each. An ownership or investment interest held by the physician or an immediate family member.
- Forte Bio-pharma LLC$1.9M
- Intra-sana Laboratories$640K
What the payments were for
- Consulting fees$15,9265%
- Speaking & faculty fees$257,26784%
- Grants$440%
- Travel & lodging$14,5835%
- Food & beverage$17,6576%
- Education$2300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 310 | $115,248 |
| Lilly USA, LLC | 134 | $49,185 |
| Amgen | 91 | $46,318 |
| Teva Pharmaceuticals USA, Inc. | 69 | $25,242 |
| Biohaven Pharmaceuticals, Inc. | 46 | $21,617 |
| Impel Pharmaceuticals Inc. | 19 | $16,181 |
| Biohaven Pharmaceutical Holding Company Ltd. | 25 | $12,245 |
| Lundbeck LLC | 53 | $11,574 |
| Novartis | 10 | $4,275 |
| Scilex Pharmaceuticals Inc. | 49 | $798 |
| Intra-sana Laboratories | 5 | $709 |
| Zyla Life Sciences, Inc. | 53 | $440 |
| Assertio Therapeutics, Inc. | 29 | $306 |
| Avanir Pharmaceuticals, Inc. | 9 | $266 |
| Upsher-smith Laboratories LLC | 10 | $206 |
| Pfizer | 9 | $195 |
| Amneal Pharmaceuticals LLC | 7 | $117 |
| Tersera Therapeutics LLC | 6 | $113 |
| Almatica Pharma LLC | 5 | $111 |
| Eli Lilly | 1 | $93 |
| Biocodex, Inc. | 1 | $85 |
| Redhill Biopharma Inc. | 1 | $71 |
| Currax Pharmaceuticals LLC | 4 | $63 |
| Jazz Pharmaceuticals Inc. | 1 | $46 |
| GRT US Holding, Inc. | 1 | $45 |
| Johnson & Johnson | 1 | $39 |
| Vertical Pharmaceuticals, LLC | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Baudax Bio Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Forte Bio-pharma LLC | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$63,789
- AIMOVIG$49,301
- QULIPTA$35,777
- BOTOX$35,660
- NURTEC ODT$33,077
- REYVOW$24,600
- AJOVY$24,485
- EMGALITY$20,361
- Trudhesa$16,026
- VYEPTI$10,819
- Reltone 200 Mg$709
- GLYCATE$709
- Reltone 400 Mg$709
- NUEDEXTA$120
How this compares
$305,708 in reported general payments places this provider in the 95th percentile of 145 neurology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 61 | $76,531 |
| UbrelvyUbrogepant | 47 | $65,794 |
| Nurtec OdtRimegepant Sulfate | 29 | $40,739 |
| Aimovig AutoinjectorErenumab-Aooe | 39 | $38,781 |
| QuliptaAtogepant | 27 | $25,010 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 19 | $14,918 |
| Sumatriptan Succinate | 51 | $4,890 |
| Sumatriptan | 12 | $2,571 |
| Eletriptan HbrEletriptan Hydrobromide | 14 | $1,684 |
| Lidocaine | 12 | $724 |
| Topiramate | 35 | $478 |
| Gabapentin | 50 | $351 |
| Methocarbamol | 22 | $220 |
| Pregabalin | 17 | $176 |
| RizatriptanRizatriptan Benzoate | 16 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy, Qulipta | $115,248 | $167,335135 claims |
| PfizerNurtec Odt | $195 | $40,73929 claims |
| Upsher-smith Laboratories LLCTopiramate | $206 | $47835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 145 neurology providers in Nevada.
Other neurology in Las Vegas
- Zoltan MariLas Vegas$629K
- Fan ZhangLas Vegas$398K
- le HuaLas Vegas$385K
- Carrie HershLas Vegas$209K
- Shanker DixitLas Vegas$137K
- Charles KamenLas Vegas$124K
- Toya MaloneLas Vegas$123K
- Nicole TheuvenetLas Vegas$120K
- Kevin XieLas Vegas$46K
- Charles BernickLas Vegas$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.